181 related articles for article (PubMed ID: 25260084)
21. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
22. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
23. [Inhibition of RANK ligand to treat bone metastases].
Body JJ
Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
[TBL] [Abstract][Full Text] [Related]
24. Role of denosumab in prostate cancer.
Helo S; Manger JP; Krupski TL
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):231-6. PubMed ID: 22370723
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer - Therapy with radium-223.
Brito AE; Amorim BJ; Martello M; Bernardo WM; Etchebehere E;
Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1019-1023. PubMed ID: 29489974
[No Abstract] [Full Text] [Related]
26. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Lipton A; Balakumaran A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
[TBL] [Abstract][Full Text] [Related]
27. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
28. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
29. Radium - 223 (Xofigo) for prostate cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1426):79-80. PubMed ID: 24081388
[No Abstract] [Full Text] [Related]
30. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
31. Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer.
Clarke NW
Eur Urol; 2014 Feb; 65(2):287-8. PubMed ID: 23948437
[No Abstract] [Full Text] [Related]
32. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
Galsky MD; Small AC; Tsao CK; Oh WK
CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
[TBL] [Abstract][Full Text] [Related]
33. [Novel drugs provide better therapy for prostate cancer].
Kellokumpu-Lehtinen P; Tammela T
Duodecim; 2013; 129(9):923-30. PubMed ID: 23786104
[TBL] [Abstract][Full Text] [Related]
34. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients.
Yee AJ; Raje NS
Clin Interv Aging; 2012; 7():331-8. PubMed ID: 22977302
[TBL] [Abstract][Full Text] [Related]
35. Novel bone-targeting agents in prostate cancer.
Albany C; Hahn NM
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):112-8. PubMed ID: 24662963
[TBL] [Abstract][Full Text] [Related]
36. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
Rolfo C; Raez LE; Russo A; Reguart N; Campelo RG; Bronte G; Papadimitriou K; Silvestris F
Expert Opin Biol Ther; 2014 Jan; 14(1):15-26. PubMed ID: 24161019
[TBL] [Abstract][Full Text] [Related]
37. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
38. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
39. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of bone metastasis with anti-RANKL antibody].
Chayahara N; Minami H
Clin Calcium; 2011 Aug; 21(8):1217-22. PubMed ID: 21814028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]